Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study.

Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood. 2011 Nov 10; 118(19):5126-9.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Alemtuzumab
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal, Murine-Derived
Antibodies, Neoplasm
Antineoplastic Agents
Disease-Free Survival
Female
Humans
Kaplan-Meier Estimate
Leukemia, Lymphocytic, Chronic, B-Cell
Male
Middle Aged
Retrospective Studies
Rituximab
Vidarabine

authors with profiles

WILLIAM G WIERDA